MBX Biosciences (MBX) Other financing activities (2023 - 2026)

MBX Biosciences has reported Other financing activities for 4 years, with the latest figure at $2.4 million in Q1 2026.

• Quarterly Other financing activities rose 60950.0% year-over-year to $2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 million (up 1018.35% YoY) and the FY2024 annual result came in at $403000.0, down 45.47% from the prior year.
• Other financing activities rose to $2.4 million in Q1 2026 per MBX's latest filing, from -$1.3 million in the prior quarter.
• Over five years, Other financing activities peaked at $174.3 million in Q3 2024 and troughed at -$174.1 million in Q4 2024.
• A 4-year average of $318222.2 and a median of $50000.0 in 2024 frame the typical range for Other financing activities.
• The sharpest annual moves came in 2024 and 2026: Other financing activities tumbled 916621.05% in 2024, then jumped 60950.0% in 2026.
• Over 4 years, Other financing activities stood at $19000.0 in 2023, then sank by 916621.05% to -$174.1 million in 2024, then soared by 99.24% to -$1.3 million in 2025, then surged by 283.61% to $2.4 million in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $2.4 million, -$1.3 million, and $1.3 million for Q1 2026, Q3 2025, and Q2 2025 respectively.